News / Events

Daiichi Sankyo Submits Yescarta NDA to Japan MHLW

Country: JAPAN | Region: ASIA & SOUTH PACIFIC | Type: Drug Approval | Keywords: #cartcelltherapy #cellandgenetherapy #daiichisankyo #genetherapy #gilead #kite
#lymphoma #mhlw #newdrugapplication

PRICENTRIC BRIEF:

  • Daiichi Sankyo has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labor, and Welfare (MHLW) for its CAR T-cell therapy Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed/refractory (R/R) diffused large B-cell lymphoma (DLBCL) and related lymphomas
  • The NDA for Yescarta is based on previous trial data that was conducted globally by Kite along with results from a Phase 2 bridging study conducted by Daiichi Sankyo
  • Both trials included patients with four aggressive types of relapsed/refractory B-cell lymphomas including diffuse large B cell lymphoma (DLBCL); primary mediastinal B-cell lymphoma (PMBCL); transformed follicular lymphoma (TFL); and high-grade B cell lymphoma

THE DETAILS

TOKYO, Japan – Daiichi Sankyo has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labor, and Welfare (MHLW) for its CAR T-cell therapy Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed/refractory (R/R) diffused large B-cell lymphoma (DLBCL) and related lymphomas.

The NDA for Yescarta is based on previous trial data that was conducted globally by Kite along with results from a Phase 2 bridging study conducted by Daiichi Sankyo.

Both trials included patients with four aggressive types of relapsed/refractory B-cell lymphomas including diffuse large B cell lymphoma (DLBCL); primary mediastinal B-cell lymphoma (PMBCL); transformed follicular lymphoma (TFL); and high-grade B cell lymphoma.

Wataru Takasaki, PhD, Corporate Officer, Head of Oncology Function and Head of R&D Division in Japan, Daiichi Sankyo, said, “We are pleased to confirm submission of the NDA for axicabtagene ciloleucel following positive topline results from the phase 2 bridging study in Japan.

“We will continue to work with regulatory authorities to develop this important new cell therapy for eligible patients in Japan who need additional treatment options for relapsed or refractory DLBCL and related lymphomas.”

 

Learn more about Pricentric One and our Global Pricing Solutions!

Contact us with your questions and global pricing needs, and an expert will follow up shortly.

Italy Experiences Drug Shortages Amid COVID-19 Outbreak

Country: ITALY | Region: EUROPE | Type: Regulation | Keywords: #aifa #antiretrovirals #assogenerici #coronavirus #covid19 #drugshortages #farmindustria PRICENTRIC BRIEF: Due to the sudden increase in demand for drugs amid the COVID-19 outbreak, Italy is currently experiencing drug supply deficiencies, and to find emergency solutions, the Italian Medicines Agency (AIFA) has turned to collaborating with pharmaceutical companies through Assogenerici and Farmindustria Enrique Hausermann, President of Assogenerici, explained that the need […]

EVERSANA™ appoints digital therapeutics pioneer Ed Cox to lead global commercialization platform for digital medicine

CHICAGO – March 18, 2020  – EVERSANA™, the leading independent provider of global commercial services to the life sciences industry, today announced the appointment of Ed Cox to Executive Vice President, Strategic Alliances & Global Head of EVERSANA’s new Digital Medicine practice area. Widely recognized as a preeminent thought leader in digital therapeutics, Cox joins […]

NHS England to Start Covering PrEP Next Month

Country: UNITED KINGDOM | Region: EUROPE | Type: Pricing & Reimbursement | Keywords: #emtricitabine/tenofovirdisoproxil #gilead #hiv #impacttrial #mylan #nhsengland #prep PRICENTRIC BRIEF: From April, pre-exposure prophylaxis (PrEP) will be available on NHS England for patients at a greater risk of catching HIV, announced Health Secretary Matt Hancock NHS England will cover the costs of the drug—according to the Department of Health, local authorities will receive GBP 16 million in 2020 […]

Vertex & Canada Pricing Alliance Back-and-Forth on CF Drug Reimbursement

Country: CANADA-ONTARIO | Region: NORTH AMERICA | Type: Pricing & Reimbursement | Keywords: #canadiancftreatmentsociety #cysticfibrosis #pancanadianpricingalliance #portfoliodeal #vertex PRICENTRIC BRIEF: Although Vertex’s three cystic fibrosis (CF) drugs Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor), and Symdeko (tezacaftor/ivacaftor and ivacaftor) are approved for use in Canada, the drugmaker and the pan-Canadian Pricing Alliance have yet to agree on reimbursement rates Vertex has reportedly made five different offers to Canada’s pricing alliance […]

EVERSANA Sponsors CADTH 2020

Analyze, Deliver, Measure, and Communicate Value Across the Product Lifecycle. EVERSANA is a Silver Sponsor of the Canadian Agency for Drugs and Technologies in Health (CADTH) in Toronto, Ontario, and  EVERSANA experts join industry colleagues to share their insight to more than 1000 attendees involved in the areas of policy-making, program decision-making, health care delivery, […]

Brazil Approved 21 Orphan Drugs in 2019

Country: BRAZIL | Region: SOUTH AMERICA | Type: Drug Approval | Keywords: #advancedtherapyproducts #anvisa #clinicaltrials #drugregistration #orphandrugs #rarediseases #regulation PRICENTRIC BRIEF: In 2019, Brazil’s National Health Surveillance Agency (ANVISA) approved 21 orphan drugs and 30 clinical trials, a record for the regulator The recent approval of Resolution of the Collegiate Board (RDC) 338/2020, which takes effect June 1, 2020, addresses the registration of advanced therapy products and the rules […]

EVERSANA Sponsors Rainmaker20

Learn how to Know and Grow Your True Top Line at Rainmaker20. Join the largest gathering of Model N users, partners, and thought leaders at the industry’s premier Revenue Management conference. You’ll gain valuable insights into how to maximize revenue at speed and scale across billions of revenue execution moments in your business, every day. […]

Belgium’s State Council Backs Confidential Agreement Transparency Bill

Country: BELGIUM | Region: EUROPE | Type: Policy | Keywords: #courtofaudit #healthministry #managedentryagreements #pricingcontracts #transparency PRICENTRIC BRIEF: The Council of State adopted a positive opinion on an SP.A and N-VA bill that would allow the Court of Audit full insight into the secret pricing contracts negotiated by the Minister of Health and pharmaceutical companies when it comes to expensive, innovative medicines The Court of Audit would only have […]

EVERSANA Sponsors Pharma Pricing & Market Access Congress 2020

UPDATE: PPMA 2020 has been postponed due to the COVID-19 Coronavirus travel bans that have been put in place. The event will take place on September 24-25, 2020.   EVERSANA is proud to be a Platinum Sponsor at this year’s World Pharma Pricing, Market Access & Evidence Congress (PPMA), taking place on September 24 and […]